-
Mashup Score: 0Supreme Court declines to hear Sandoz's appeal for Enbrel biosimilar, upholds Amgen patent - 3 year(s) ago
The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market. In July 2020, the U.S. Court of Appeals for the Federal Circuit ruled in a 2-1 decision that the Sandoz biosimilar Erelzi (etanercept-szzs) infringed
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 2Supreme Court declines to hear Sandoz's appeal for Enbrel biosimilar, upholds Amgen patent - 3 year(s) ago
The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market. In July 2020, the U.S. Court of Appeals for the Federal Circuit ruled in a 2-1 decision that the Sandoz biosimilar Erelzi (etanercept-szzs) infringed
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
The U.S. #SupremeCourt has denied a petition from #Novartis’ #Sandoz to review an earlier U.S. appeals court ruling in favor of #Amgen’s #etanercept against etanercept-szzs, effectively blocking the #biosimilar from entering the U.S. market https://t.co/EPsIg9hgRI
-
-
Mashup Score: 2Etanercept retreatment feasible in people with JIA - 3 year(s) ago
Etanercept is effective in the retreatment of patients with juvenile idiopathic arthritis who have a disease flare after previously achieving inactive disease on the biologic DMARD, research suggests.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: Patients with #JIA benefit from retreatment with #etanercept when they have a disease flare after previously achieving inactive disease with the biologic, say Jens Klotsche (@DRFZ_Berlin) et al in @ArthritisRes https://t.co/Sjjs8GHMw5
-
-
Mashup Score: 0Etanercept Shows Greater Improvements in Treating Psoriatic Arthritis Than MTX Monotherapy - 3 year(s) ago
In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with psoriatic arthritis receiving methotrexate monotherapy, etanercept monotherapy, or a combination of both drugs.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
A recent study showed that #etanercept monotherapy and combination therapy were more successful at treating #PsA symptoms and improving patient-reported outcomes compared with #MTX alone. Read more: https://t.co/fzzgkLQWGh
-
-
Mashup Score: 0Etanercept Shows Greater Improvements in Treating Psoriatic Arthritis Than MTX Monotherapy - 3 year(s) ago
In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with psoriatic arthritis receiving methotrexate monotherapy, etanercept monotherapy, or a combination of both drugs.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
In order to improve quality of life for patients with #psoriaticarthritis, investigators examined the effectiveness of #etanercept (a tumor necrosis factor inhibitor) monotherapy, #methotrexate monotherapy, and combination therapy. Learn more: https://t.co/fzzgkM8y4R
-
-
Mashup Score: 2Etanercept Shows Greater Improvements in Treating Psoriatic Arthritis Than MTX Monotherapy - 3 year(s) ago
In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with psoriatic arthritis receiving methotrexate monotherapy, etanercept monotherapy, or a combination of both drugs.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with #psoriaticarthritis receiving #methotrexate monotherapy, #etanercept monotherapy, or a combination of both drugs. https://t.co/fzzgkM8y4R
-
-
Mashup Score: 0
Individuals with active polyarticular juvenile idiopathic arthritis are more likely to respond to early treatment with etanercept plus methotrexate than with methotrexate alone, trial findings indicate.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: Early addition of #etanercept to #methotrexate increases response rates and shortens the time to remission vs methotrexate monotherapy in active polyarticular juvenile idiopathic #arthritis, researchers report in Pediatric Rheumatology @BioMedCentral https://t.co/qZWJcdUPQ3
-
-
Mashup Score: 1
Jeffrey Curtis talks about the SEAM-RA trial, which compared etanercept versus methotrexate withdrawal among rheumatoid arthritis patients who were in sustained remission on combination therapy with both agents.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
SEAM-RA trial results, demonstrating better remission maintenance with #etanercept vs #methotrexate monotherapy in #RheumatoidArthritis, now published in @ACR_Journals. Click through to listen to our interview with lead investigator Jeffrey Curtis #ACR20 https://t.co/oIv0fRbOle
-
-
Mashup Score: 2
In patients with rheumatoid arthritis who achieve remission with combination therapy and then withdraw either etanercept or methotrexate, monotherapy with the former is superior to the latter for remission maintenance, noted a speaker here.“For those patients with RA who are in remission on combination therapy — for example, methotrexate — and a TNF inhibitor such as etanercept,
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
In patients with #rheumatoidarthritis who achieve remission with combination therapy and then withdraw either #etanercept or methotrexate, monotherapy with the former is superior to the latter, said Dr Jeffrey Curtis @UABSOM at #ACR20 https://t.co/CIbekJScJ9
-
-
Mashup Score: 1Better maintenance of remission with etanercept vs methotrexate monotherapy in the SEAM-RA trial - 4 year(s) ago
Among rheumatoid arthritis patients in sustained remission on combination therapy, withdrawal of methotrexate is associated with better outcomes than withdrawal of etanercept, indicate findings from the SEAM-RA trial.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR20 news: SEAM-RA trial shows better outcomes with withdrawal of #methotrexate vs #etanercept in #RheumatoidArthritis patients who achieve sustained remission on combination therapy, reports Jeffrey Curtis @RADoctor https://t.co/RSLeqDgxs1
-
#SupremeCourt denied a #Sandoz petition requesting the court review an earlier ruling that blocked its #etanercept #biosimilar from entering the U.S. market on the grounds of patent infringement https://t.co/EPsIg9hgRI